<?xml version="1.0" encoding="UTF-8"?>
<p>Dosing for boceprevir (according to product labeling): HCV treatment na√Øve patients and relapsers received boceprevir for 24 to 44 weeks and 36 to 48 weeks respectively in addition to Peg-IFN/RBV for 28 to 48 weeks. Treatment duration was dependent on patient response after 4 weeks of treatment. Prior non-responders or patients with compensated cirrhosis received boceprevir for 44 weeks and Peg-IFN/RBV for 48 weeks.</p>
